Ernesto L Schiffrin

List of Publications by Year
in descending order

556 papers	42,047 citations	1792 103 h-index	3312 184 g-index
580 all docs	580 docs citations	580 times ranked	33659 citing authors

#	Article	IF	Citations
1	The Metabolic Syndrome and Cardiovascular Risk. Journal of the American College of Cardiology, 2010, 56, 1113-1132.	1.2	2,179
2	Chronic Kidney Disease. Circulation, 2007, 116, 85-97.	1.6	1,278
3	Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness. Hypertension, 2015, 66, 698-722.	1.3	1,073
4	Endothelial Dysfunction. Journal of the American Society of Nephrology: JASN, 2004, 15, 1983-1992.	3.0	1,034
5	Vascular Remodeling in Hypertension. Hypertension, 2001, 38, 581-587.	1.3	849
6	Clinical Practice Guidelines for the Management of Hypertension in the Community. Journal of Clinical Hypertension, 2014, 16, 14-26.	1.0	768
7	Expression of a Functionally Active gp91phox-Containing Neutrophil-Type NAD(P)H Oxidase in Smooth Muscle Cells From Human Resistance Arteries. Circulation Research, 2002, 90, 1205-1213.	2.0	558
8	Endothelial function and dysfunction. Part I. Journal of Hypertension, 2005, 23, 7-17.	0.3	553
9	Clinical Practice Guidelines for the Management of Hypertension in the Community. Journal of Hypertension, 2014, 32, 3-15.	0.3	498
10	Hypertension Canadaâ€™s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2018, 34, 506-525.	0.8	474
11	Angiotensin-(1-7) Through Receptor Mas Mediates Endothelial Nitric Oxide Synthase Activation via Akt-Dependent Pathways. Hypertension, 2007, 49, 185-192.	1.3	470
12	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2015, 31, 549-568.	0.8	431
13	Structure and Mechanical Properties of Resistance Arteries in Hypertension. Hypertension, 2000, 36, 312-318.	1.3	403
14	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2016, 32, 569-588.	0.8	400
15	Impaired Tissue Perfusion. Circulation, 2008, 118, 968-976.	1.6	398
16	Management of High Blood Pressure in African Americans<subtitle>Consensus Statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks</subtitle>. Archives of Internal Medicine, 2003, 163, 525.	4.3	393
17	Spironolactone Improves Angiotensin-Induced Vascular Changes and Oxidative Stress. Hypertension, 2002, 40, 504-510.	1.3	373
18	T Regulatory Lymphocytes Prevent Angiotensin IIâ€“Induced Hypertension and Vascular Injury. Hypertension, 2011, 57, 469-476.	1.3	371

#	Article	IF	Citations
19	Role of the reninâ€“angiotensin system in vascular inflammation. Trends in Pharmacological Sciences, 2008, 29, 367-374.	4.0	368
20	Antioxidant Effects of Vitamins C and E Are Associated With Altered Activation of Vascular NADPH Oxidase and Superoxide Dismutase in Stroke-Prone SHR. Hypertension, 2001, 38, 606-611.	1.3	345
21	Structure, Endothelial Function, Cell Growth, and Inflammation in Blood Vessels of Angiotensin Iiâ€“Infused Rats. Circulation, 2002, 105, 2296-2302.	1.6	339
22	Hypertension Canadaâ€™s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2020, 36, 596-624.	0.8	324
23	Endothelium-Restricted Overexpression of Human Endothelin-1 Causes Vascular Remodeling and Endothelial Dysfunction. Circulation, 2004, 110, 2233-2240.	1.6	296
24	Reduced Vascular Remodeling, Endothelial Dysfunction, and Oxidative Stress in Resistance Arteries of Angiotensin Iiâ€“Infused Macrophage Colony-Stimulating Factorâ€“Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2106-2113.	1.1	293
25	Aldosterone: effects on the kidney and cardiovascular system. Nature Reviews Nephrology, 2010, 6, 261-273.	4.1	286
26	Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. American Journal of Hypertension, 2004, 17, 1192-1200.	1.0	281
27	ATRIAL NATRIURETIC FACTOR INHIBITS THE STIMULATION OF ALDOSTERONE SECRETION BY ANGIOTENSIN II, ACTH AND POTASSIUMIN VITROAND ANGIOTENSIN II-INDUCED STEROIDOGENESISIN VIVO.. Endocrinology, 1984, 115, 2026-2028.	1.4	280
28	Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clinical Science, 2007, 112, 375-384.	1.8	276
29	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Canadian Journal of Cardiology, 2017, 33, 557-576.	0.8	269
30	Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. Journal of Hypertension, 2001, 19, 921-930.	0.3	267
31	Hypertension and COVID-19. American Journal of Hypertension, 2020, 33, 373-374.	1.0	260
32	Effects of Aldosterone on the Vasculature. Hypertension, 2006, 47, 312-318.	1.3	257
33	Vascular endothelin in hypertension. Vascular Pharmacology, 2005, 43, 19-29.	1.0	239
34	Angiotensin-(1-7) Counterregulates Angiotensin II Signaling in Human Endothelial Cells. Hypertension, 2007, 50, 1093-1098.	1.3	239
35	Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. Journal of Hypertension, 2001, 19, 1245-1254.	0.3	234
36	Endothelin Antagonism on Aldosterone-Induced Oxidative Stress and Vascular Remodeling. Hypertension, 2003, 42, 49-55.	1.3	227

#	Article	IF	Citations
37	PPARÎ± Activator Effects on Ang IIâ€“Induced Vascular Oxidative Stress and Inflammation. Hypertension, 2002, 40, 866-871.	1.3	221
38	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and TreatmentÂof Hypertension. Canadian Journal of Cardiology, 2014, 30, 485-501.	0.8	221
39	From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H435-H446.	1.5	220
40	Aldosterone Activates Vascular p38MAP Kinase and NADPH Oxidase Via c-Src. Hypertension, 2005, 45, 773-779.	1.3	220
41	Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. Journal of Hypertension, 2004, 22, 535-542.	0.3	218
42	Endothelial Nitric Oxide Synthase Uncoupling and Perivascular Adipose Oxidative Stress and Inflammation Contribute to Vascular Dysfunction in a Rodent Model of Metabolic Syndrome. Hypertension, 2009, 54, 1384-1392.	1.3	214
43	Plasma Endothelin in Human Essential Hypertension. American Journal of Hypertension, 1991, 4, 303-308.	1.0	202
44	Resistance Artery Mechanics, Structure, and Extracellular Components in Spontaneously Hypertensive Rats. Circulation, 1999, 100, 2267-2275.	1.6	202
45	Vascular Remodeling in Hypertension. Hypertension, 2012, 59, 367-374.	1.3	201
46	Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clinical and Experimental Pharmacology and Physiology, 2003, 30, 860-866.	0.9	195
47	T Regulatory Lymphocytes Prevent Aldosterone-Induced Vascular Injury. Hypertension, 2012, 59, 324-330.	1.3	194
48	Ang IIâ€“Stimulated Superoxide Production Is Mediated via Phospholipase D in Human Vascular Smooth Muscle Cells. Hypertension, 1999, 34, 976-982.	1.3	192
49	Isolated Aerobic Exercise and Weight Loss: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. American Journal of Medicine, 2011, 124, 747-755.	0.6	192
50	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 â€“ therapy. Canadian Journal of Cardiology, 2010, 26, 249-258.	0.8	191
51	Effect of Peroxisome Proliferatorâ€“Activated Receptor-Î± and -Î³ Activators on Vascular Remodeling in Endothelin-Dependent Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 45-51.	1.1	188
52	Radioautographic localization of specific binding sites for blood-borne angiotensin II in the rat brain. Brain Research, 1980, 186, 480-485.	1.1	186
53	Chronic treatment with a superoxide dismutase mimetic prevents vascular remodeling and progression of hypertension in salt-loaded stroke-prone spontaneously hypertensive rats. American Journal of Hypertension, 2002, 15, 78-84.	1.0	183
54	Twisting integrin receptors increases endothelin-1 gene expression in endothelial cells. American Journal of Physiology - Cell Physiology, 2001, 280, C1475-C1484.	2.1	178

#	Article	IF	Citations
55	Role of Endothelin-1 in Hypertension. Hypertension, 1999, 34, 876-881.	1.3	177
56	Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. Journal of Hypertension, 2004, 22, 1141-1149.	0.3	175
57	Inflammation in hypertension. Current Opinion in Internal Medicine, 2006, 5, 245-251.	1.5	175
58	The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2012, 28, 270-287.	0.8	173
59	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I â€“ blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2010, 26, 241-248.	0.8	170
60	Mechanics and Composition of Human Subcutaneous Resistance Arteries in Essential Hypertension. Hypertension, 1999, 33, 569-574.	1.3	167
61	Docosahexaenoic Acid, a Peroxisome Proliferatorâ€“Activated Receptor-Î± Ligand, Induces Apoptosis in Vascular Smooth Muscle Cells by Stimulation of p38 Mitogen-Activated Protein Kinase. Hypertension, 2000, 36, 851-855.	1.3	165
62	PPARÎ± activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. Journal of Molecular and Cellular Cardiology, 2004, 36, 295-304.	0.9	163
63	The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2013, 29, 528-542.	0.8	163
64	Structure and function of resistance arteries of hypertensive patients treated with a p-blocker or a calcium channel antagonist. Journal of Hypertension, 1996, 14, 1247-1255.	0.3	160
65	Vascular inflammation: a role in vascular disease in hypertension?. Current Opinion in Nephrology and Hypertension, 2003, 12, 181-187.	1.0	160
66	Comparison of Effects of Angiotensin Iâ€“ Converting Enzyme Inhibition and Î²-Blockade for 2 Years on Function of Small Arteries From Hypertensive Patients. Hypertension, 1995, 25, 699-703.	1.3	159
67	Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. Journal of Hypertension, 1997, 15, 57-63.	0.3	158
68	Selective Mineralocorticoid Receptor Blocker Eplerenone Reduces Resistance Artery Stiffness in Hypertensive Patients. Hypertension, 2008, 51, 432-439.	1.3	156
69	Aldosterone and Angiotensin II Synergistically Stimulate Migration in Vascular Smooth Muscle Cells Through c-Src-Regulated Redox-Sensitive RhoA Pathways. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1511-1518.	1.1	153
70	Angiotensin Type 2 Receptor Agonist Compound 21 Reduces Vascular Injury and Myocardial Fibrosis in Stroke-Prone Spontaneously Hypertensive Rats. Hypertension, 2012, 59, 291-299.	1.3	151
71	Role of Endothelin-1 in Clinical Hypertension. Hypertension, 2008, 52, 452-459.	1.3	150
72	Peroxisome Proliferator-Activated Receptors. Hypertension, 2003, 42, 664-668.	1.3	149

#	Article	IF	Citations
73	Immune mechanisms in hypertension and vascular injury. Clinical Science, 2014, 126, 267-274.	1.8	149
74	Myocardial Fibrosis in DOCA-Salt Hypertensive Rats. Circulation, 2001, 103, 319-324.	1.6	148
75	Role of AT ‹sub›2‹/sub› Receptors in Angiotensin IIâ€“Stimulated Contraction of Small Mesenteric Arteries in Young SHR. Hypertension, 1999, 33, 366-372.	1.3	145
76	The angiotensin II type 2 receptor in cardiovascular disease. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2010, 11, 19-31.	1.0	145
77	Peroxisome Proliferator-Activated Receptor-Î± and Receptor-Î³ Activators Prevent Cardiac Fibrosis in Mineralocorticoid-Dependent Hypertension. Hypertension, 2003, 42, 737-743.	1.3	144
78	Vascular stiffening and arterial complianceImplications for systolic blood pressure. American Journal of Hypertension, 2004, 17, S39-S48.	1.0	144
79	Fibrosis, Matrix Metalloproteinases, and Inflammation in the Heart of DOCA-Salt Hypertensive Rats: Role of ETAReceptors. Hypertension, 2002, 39, 679-684.	1.3	143
80	Beyond blood pressure: the endothelium and atherosclerosis progression*. American Journal of Hypertension, 2002, 15, 115S-122S.	1.0	143
81	Î³Î´ T Cells Mediate Angiotensin II-Induced Hypertension and Vascular Injury. Circulation, 2017, 135, 2155-2162.	1.6	142
82	Vascular Actions of Aldosterone. Journal of Vascular Research, 2013, 50, 89-99.	0.6	140
83	Role of Inflammation and Immunity in Hypertension: Recent Epidemiological, Laboratory, and Clinical Evidence. Current Hypertension Reports, 2016, 18, 21.	1.5	139
84	ET A Receptor Blockade Decreases Vascular Superoxide Generation in DOCA-Salt Hypertension. Hypertension, 2003, 42, 811-817.	1.3	134
85	Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascular Pharmacology, 2006, 45, 19-28.	1.0	133
86	Role of endothelin in human hypertension. Canadian Journal of Physiology and Pharmacology, 2003, 81, 533-541.	0.7	132
87	Vascular Mechanisms in the Pathogenesis of Stroke. Current Hypertension Reports, 2011, 13, 200-207.	1.5	130
88	Differential Calcium Regulation by Hydrogen Peroxide and Superoxide in Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2004, 44, 200-208.	0.8	127
89	The 2011 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2011, 27, 415-433.e2.	0.8	127
90	Angiotensin Type 2 Receptor in Resistance Arteries of Type 2 Diabetic Hypertensive Patients. Hypertension, 2007, 49, 341-346.	1.3	125

#	Article	IF	Citations
91	Effect of atrial natriuretic factor (ANF)-related peptides on aldosterone secretion by adrenal glomerulosa cells: Critical role of the intramolecular disulphide bond. Biochemical and Biophysical Research Communications, 1984, 122, 171-174.	1.0	123
92	Effectiveness of Renal Denervation Therapy forÂResistant Hypertension. Journal of the American College of Cardiology, 2013, 62, 231-241.	1.2	122
93	Vascular and cardiac benefits of angiotensin receptor blockers. American Journal of Medicine, 2002, 113, 409-418.	0.6	119
94	Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. American Journal of Hypertension, 2002, 15, 164-169.	1.0	119
95	Role of Extracellular Signal-Regulated Kinases in Angiotensin IIâ€“Stimulated Contraction of Smooth Muscle Cells From Human Resistance Arteries. Circulation, 1999, 99, 392-399.	1.6	114
96	The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II â€“ Therapy. Canadian Journal of Cardiology, 2006, 22, 583-593.	0.8	113
97	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 â€“ therapy. Canadian Journal of Cardiology, 2009, 25, 287-298.	0.8	111
98	Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. Journal of Hypertension, 2002, 20, 71-78.	0.3	108
99	Effect of aldosterone on vascular angiotensin II receptors in the rat. Canadian Journal of Physiology and Pharmacology, 1985, 63, 1522-1527.	0.7	107
100	Persistent Remodeling of Resistance Arteries in Type 2 Diabetic Patients on Antihypertensive Treatment. Hypertension, 2004, 43, 399-404.	1.3	107
101	Immune regulation and vascular inflammation in genetic hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 298, H938-H944.	1.5	107
102	ET A Receptor Antagonist Prevents Blood Pressure Elevation and Vascular Remodeling in Aldosterone-Infused Rats. Hypertension, 2001, 37, 1444-1449.	1.3	106
103	Effect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review. American Journal of Medicine, 2009, 122, 962.e1-962.e8.	0.6	106
104	Correlation of endothelial function in large and small arteries in human essential hypertension.. Journal of Hypertension, 2001, 19, 415-420.	0.3	105
105	Aldosterone, Inflammation, Immune System, and Hypertension. American Journal of Hypertension, 2021, 34, 15-27.	1.0	105
106	Oxidative Stress, Nox Isoforms and Complications of Diabetesâ€”Potential Targets for Novel Therapies. Journal of Cardiovascular Translational Research, 2012, 5, 509-518.	1.1	104
107	Eplerenone Prevents Salt-Induced Vascular Remodeling and Cardiac Fibrosis in Stroke-Prone Spontaneously Hypertensive Rats. Hypertension, 2004, 43, 1252-1257.	1.3	103
108	Role of immune cells in hypertension. British Journal of Pharmacology, 2019, 176, 1818-1828.	2.7	103

#	Article	IF	Citations
109	Vascular consequences of inflammation: a position statement from the ESH Working Group on Vascular Structure and Function and the ARTERY Society. Journal of Hypertension, 2020, 38, 1682-1698.	0.3	102
110	Blunted effects of endothelin upon small subcutaneous resistance arteries of mild essential hypertensive patients. Journal of Hypertension, 1992, 10, 437-444.	0.3	101
111	Angiotensin II stimulates DNA and protein synthesis in vascular smooth muscle cells from human arteries. Journal of Hypertension, 1999, 17, 907-916.	0.3	101
112	Redox-dependent MAP kinase signaling by Ang II in vascular smooth muscle cells: role of receptor tyrosine kinase transactivation. Canadian Journal of Physiology and Pharmacology, 2003, 81, 159-167.	0.7	101
113	Peroxisome proliferator-activated receptors and cardiovascular remodeling. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H1037-H1043.	1.5	100
114	A Critical Review of the Role of Endothelial Factors in the Pathogenesis of Hypertension. Journal of Cardiovascular Pharmacology, 2001, 38, S3-S6.	0.8	99
115	Plasma levels of matrix metalloproteinases and their inhibitors in hypertension. Journal of Hypertension, 2012, 30, 3-16.	0.3	99
116	Effect of Chronic Treatment of Adult Spontaneously Hypertensive Rats With an Endothelin Receptor Antagonist. Hypertension, 1995, 25, 495-500.	1.3	99
117	Deoxycorticosterone Acetate Plus Salt Induces Overexpression of Vascular Endothelin-1 and Severe Vascular Hypertrophy in Spontaneously Hypertensive Rats. Hypertension, 1995, 25, 769-773.	1.3	99
118	Resistance artery remodeling in deoxycorticosterone acetate-salt hypertension is dependent on vascular inflammation: evidence from m-CSF-deficient mice. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H1789-H1795.	1.5	98
119	Structural and Functional Alterations of Subcutaneous Small Resistance Arteries in Severe Human Obesity. Obesity, 2010, 18, 92-98.	1.5	98
120	The Immune System: Role in Hypertension. Canadian Journal of Cardiology, 2013, 29, 543-548.	0.8	98
121	Src Is an Important Mediator of Extracellular Signalâ€“Regulated Kinase 1/2â€“Dependent Growth Signaling by Angiotensin II in Smooth Muscle Cells From Resistance Arteries of Hypertensive Patients. Hypertension, 2001, 38, 56-64.	1.3	97
122	Combined Angiotensin II Type 1 and Type 2 Receptor Blockade on Vascular Remodeling and Matrix Metalloproteinases in Resistance Arteries. Hypertension, 2005, 46, 598-606.	1.3	96
123	Redox-Sensitive Signaling by Angiotensin II Involves Oxidative Inactivation and Blunted Phosphorylation of Protein Tyrosine Phosphatase SHP-2 in Vascular Smooth Muscle Cells From SHR. Circulation Research, 2008, 103, 149-158.	2.0	96
124	T lymphocytes: a role in hypertension?. Current Opinion in Nephrology and Hypertension, 2010, 19, 181-186.	1.0	96
125	Increased Angiotensin II-Mediated Src Signaling via Epidermal Growth Factor Receptor Transactivation Is Associated With Decreased C-Terminal Src Kinase Activity in Vascular Smooth Muscle Cells From Spontaneously Hypertensive Rats. Hypertension, 2002, 39, 479-485.	1.3	94
126	Endothelium-Dependent Relaxation of Small Arteries from Essential Hypertensive Patients: Mechanisms and Comparison with Normotensive Subjects and with Responses of Vessels from Spontaneously Hypertensive Rats. Clinical Science, 1995, 88, 611-622.	1.8	93

#	Article	IF	Citations
127	Effects of enalapril and amlodipine on small-artery structure and composition, and on endothelial dysfunction in spontaneously hypertensive rats. Journal of Hypertension, 1998, 16, 457-466.	0.3	93
128	New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. Journal of Molecular Medicine, 2008, 86, 673-678.	1.7	93
129	The atrial natriuretic factor: Its physiology and biochemistry. Reviews of Physiology, Biochemistry and Pharmacology, 1988, 110, 1-145.	0.9	92
130	Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats. Journal of Hypertension, 2005, 23, 1037-1045.	0.3	92
131	Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H281-H288.	1.5	92
132	Abnormal Adrenal and Vascular Responses to Vasopressin Mediated by a V₁-Vasopressin Receptor in a Patient with Adrenocorticotropin-Independent Macronodular Adrenal Hyperplasia, Cushingâ€™s Syndrome, and Orthostatic Hypotension¹. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2414-2422.	1.8	90
133	In Vivo Study of AT 1 and AT 2 Angiotensin Receptors in Apoptosis in Rat Blood Vessels. Hypertension, 1999, 34, 617-624.	1.3	90
134	Endothelin-1 and Angiotensin II Receptors in Cells From Rat Hypertrophied Heart. Circulation Research, 1996, 78, 302-311.	2.0	90
135	Decreased density of binding sites for atrial natriuretic peptide on platelets of patients with severe congestive heart failure. Clinical Science, 1988, 74, 213-218.	1.8	89
136	How to assess vascular remodelling in small and medium-sized muscular arteries in humans. Journal of Hypertension, 1997, 15, 571-584.	0.3	89
137	Endothelin and endothelin antagonists in hypertension. Journal of Hypertension, 1998, 16, 1891-1895.	0.3	89
138	c-Srcâ€“Dependent Nongenomic Signaling Responses to Aldosterone Are Increased in Vascular Myocytes From Spontaneously Hypertensive Rats. Hypertension, 2005, 46, 1032-1038.	1.3	89
139	Disappearance of atrial natriuretic factor from circulation in the rat. Peptides, 1986, 7, 241-246.	1.2	88
140	Role of c-Src in the regulation of vascular contraction and Ca2+ signaling by angiotensin II in human vascular smooth muscle cells. Journal of Hypertension, 2001, 19, 441-449.	0.3	88
141	Involvement of oxidative stress in the profibrotic action of aldosteroneInteraction with the renin-angiotensin system. American Journal of Hypertension, 2004, 17, 597-603.	1.0	88
142	Angiotensin Receptor Blocker Added to Previous Antihypertensive Agents on Arteries of Diabetic Hypertensive Patients. Hypertension, 2006, 48, 271-277.	1.3	88
143	The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 â€“ therapy. Canadian Journal of Cardiology, 2007, 23, 539-550.	0.8	87
144	Enhanced Expression of the Endothelin-1 Gene in Blood Vessels of DOCA-Salt Hypertensive Rats: Correlation with Vascular Structure. Journal of Vascular Research, 1996, 33, 235-248.	0.6	86

#	Article	IF	Citations
145	Endothelin-1 Overexpression Exacerbates Atherosclerosis and Induces Aortic Aneurysms in Apolipoprotein E Knockout Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2306-2315.	1.1	86
146	Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients. American Journal of Hypertension, 2002, 15, 105-110.	1.0	85
147	Aldosterone-Induced Activation of Signaling Pathways Requires Activity of Angiotensin Type 1a Receptors. Circulation Research, 2009, 105, 852-859.	2.0	85
148	Nitric oxide, oxidative excess, and vascular complications of diabetes mellitus. Current Hypertension Reports, 2004, 6, 85-89.	1.5	84
149	Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support. Clinical Science, 2006, 110, 483-489.	1.8	84
150	Apoptosis in vasculature of spontaneously hypertensive rats *1Effect of an angiotensin converting enzyme inhibitor and a calcium channel antagonist. American Journal of Hypertension, 1998, 11, 1108-1116.	1.0	83
151	Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy. Canadian Journal of Physiology and Pharmacology, 2005, 83, 999-1006.	0.7	82
152	p38 MAP Kinase Regulates Vascular Smooth Muscle Cell Collagen Synthesis by Angiotensin II in SHR But Not in WKY. Hypertension, 2001, 37, 574-580.	1.3	81
153	Deficiency of T-regulatory cells exaggerates angiotensin II-induced microvascular injury by enhancing immune responses. Journal of Hypertension, 2016, 34, 97-108.	0.3	79
154	Effect of AT1 Angiotensin-Receptor Blockade on Structure and Function of Small Arteries in SHR. Journal of Cardiovascular Pharmacology, 1997, 30, 75-83.	0.8	79
155	Effects of AT 1 and AT 2 Angiotensin Receptor Antagonists in Angiotensin II-Infused Rats. Hypertension, 1998, 31, 487-492.	1.3	78
156	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 â€“ therapy. Canadian Journal of Cardiology, 2008, 24, 465-475.	0.8	78
157	The Role of Aldosterone in the Metabolic Syndrome. Current Hypertension Reports, 2011, 13, 163-172.	1.5	78
158	Effect of Hyperhomocystinemia and Hypertension on Endothelial Function in Methylenetetrahydrofolate Reductaseâ€“Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1352-1357.	1.1	76
159	Antioxidants in Hypertension and Cardiovascular Disease. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2010, 10, 354-362.	3.4	75
160	Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system. American Journal of Hypertension, 2004, 17, 597-603.	1.0	75
161	Vascular smooth muscle cell NAD(P)H oxidase activity during the development of hypertension: Effect of angiotensin II and role of insulinlike growth factor-1 receptor transactivation. American Journal of Hypertension, 2005, 18, 81-87.	1.0	74
162	Assessment and pathophysiology of microvascular disease: recent progress and clinical implications. European Heart Journal, 2021, 42, 2590-2604.	1.0	74

#	Article	IF	Citations
163	Oxidative Stress, Nitric Oxide Synthase, and Superoxide Dismutase. Hypertension, 2008, 51, 31-32.	1.3	73
164	Role of Mineralocorticoid Receptor Antagonists in Cardiovascular Disease. Circulation Research, 2015, 116, 206-213.	2.0	73
165	Clinical significance of endothelin in cardiovascular disease. Current Opinion in Cardiology, 1997, 12, 354-367.	0.8	72
166	Increased Expression of Peroxisome Proliferator-Activated Receptor-Î± and -Î³ in Blood Vessels of Spontaneously Hypertensive Rats. Hypertension, 2001, 38, 249-254.	1.3	71
167	Increased endothelium-1 gene expression in the endothelium of coronary arteries and endocardium in the DOCA-salt hypertensive rat. Journal of Molecular and Cellular Cardiology, 1995, 27, 2123-2131.	0.9	70
168	Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase. Journal of Hypertension, 2006, 24, 2417-2422.	0.3	70
169	Endothelin in hypertension. Current Opinion in Nephrology and Hypertension, 2012, 21, 128-136.	1.0	70
170	Antihypertensive effect of an endothelin receptor antagonist in DOCAâ€salt spontaneously hypertensive rats. British Journal of Pharmacology, 1995, 115, 1377-1381.	2.7	69
171	Differential activation of extracellular signal-regulated protein kinase 1/2 and p38 mitogen activated-protein kinase by AT1 receptors in vascular smooth muscle cells from Wistarâ€“Kyoto rats and spontaneously hypertensive rats. Journal of Hypertension, 2001, 19, 553-559.	0.3	69
172	Treatment of Arterial Remodeling in Essential Hypertension. Current Hypertension Reports, 2013, 15, 3-9.	1.5	69
173	Effects of Endothelin-1 and Vasopressin on Resistance Arteries of Spontaneously Hypertensive Rats. American Journal of Hypertension, 1992, 5, 817-822.	1.0	68
174	Immune Mechanisms in Hypertension. Current Hypertension Reports, 2011, 13, 465-472.	1.5	68
175	Dual opposing roles of adaptive immunity in hypertension. European Heart Journal, 2014, 35, 1238-1244.	1.0	68
176	Apoptosis in aorta of deoxycorticosterone acetate-salt hypertensive rats. Journal of Hypertension, 1997, 15, 1441-1448.	0.3	67
177	â€œSmall Blood Vessels: Big Health Problems?â€: Scientific Recommendations of the National Institutes of Health Workshop. Journal of the American Heart Association, 2016, 5, .	1.6	67
178	Vasopeptidase Inhibition Has Potent Effects on Blood Pressure and Resistance Arteries in Stroke-Prone Spontaneously Hypertensive Rats. Hypertension, 2000, 35, 1221-1225.	1.3	66
179	Reduction of resistance artery stiffness by treatment with the AT1-receptor antagonist losartan in essential hypertension. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2000, 1, 40-45.	1.0	65
180	Long-Term Use of Angiotensin Receptor Blockers and the Risk of Cancer. PLoS ONE, 2012, 7, e50893.	1.1	65

#	Article	IF	Citations
181	Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells. Steroids, 2011, 76, 834-9.	0.8	64
182	Matrix metalloproteinase-2 knockout prevents angiotensin II-induced vascular injury. Cardiovascular Research, 2017, 113, 1753-1762.	1.8	64
183	P2X7 Receptors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 186-199.	1.1	63
184	Exposure to Moderate Arsenic Concentrations Increases Atherosclerosis in ApoEâ^'/â^' Mouse Model. Toxicological Sciences, 2011, 122, 211-221.	1.4	62
185	Effect of chronic ETA -selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats. British Journal of Pharmacology, 1997, 121, 935-940.	2.7	61
186	The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2005, 21, 645-56.	0.8	61
187	Multiple actions of angiotensin II in hypertension. Journal of the American College of Cardiology, 2003, 42, 911-913.	1.2	60
188	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 â€“ blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2009, 25, 279-286.	0.8	60
189	Mitogen-Activated Protein Kinaseâ€“Activated Protein Kinase 2 in Angiotensin IIâ€“Induced Inflammation and Hypertension. Hypertension, 2011, 57, 245-254.	1.3	60
190	Long-Term Effects of 4 Popular Diets on Weight Loss and Cardiovascular Risk Factors. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 815-827.	0.9	60
191	Effect of Pressurization on Mechanical Properties of Mesenteric Small Arteries from Spontaneously Hypertensive Rats. Journal of Vascular Research, 1997, 34, 117-125.	0.6	59
192	Role of endothelin-1 in hypertension. Current Hypertension Reports, 2003, 5, 144-148.	1.5	59
193	Effect of Calcium Channel Blockade or Angiotensin-Converting Enzyme Inhibition on Structure of Coronary, Renal, and Other Small Arteries in Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 1996, 28, 68-74.	0.8	58
194	Effect of Hypertension Induced by Nitric Oxide Synthase Inhibition on Structure and Function of Resistance Arteries in the Rat. Clinical and Experimental Hypertension, 1993, 15, 527-537.	0.5	57
195	Regulation of Plasma Endothelin by Salt in Salt-Sensitive Hypertension. Circulation, 2001, 103, 263-268.	1.6	57
196	Mesenteric vascular smooth muscle cells from spontaneously hypertensive rats display increased calcium responses to angiotensin II but not to endothelin-1. Journal of Hypertension, 1994, 12, 663???674.	0.3	56
197	The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I â€“ Blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2006, 22, 573-581.	0.8	56
198	PPAR-Î³ inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H390-H397.	1.5	56

#	Article	IF	Citations
199	Peroxisome Proliferatorâ€“Activated Receptor Î³ Regulates Angiotensin IIâ€“Stimulated Phosphatidylinositol 3-Kinase and Mitogen-Activated Protein Kinase in Blood Vessels In Vivo. Hypertension, 2006, 47, 102-108.	1.3	56
200	Prevalence of Diabetes and Hypertension and Their Associated Risks for Poor Outcomes in Covid-19 Patients. Journal of the Endocrine Society, 2020, 4, bvaa102.	0.1	56
201	The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Canadian Journal of Cardiology, 2005, 21, 657-72.	0.8	56
202	Inhibition of mitogen-activated protein/extracellular signal-regulated kinase improves endothelial function and attenuates Ang II-induced contractility of mesenteric resistance arteries from spontaneously hypertensive rats. Journal of Hypertension, 2002, 20, 1127-1134.	0.3	55
203	Transient Neonatal High Oxygen Exposure Leads to Early Adult Cardiac Dysfunction, Remodeling, and Activation of the Reninâ€“Angiotensin System. Hypertension, 2014, 63, 143-150.	1.3	55
204	Vascular Structure and Expression of Endothelin-1 Gene in L-NAMEâ€“Treated Spontaneously Hypertensive Rats. Hypertension, 1996, 27, 49-55.	1.3	55
205	Effect of AT₁ receptor blockade on cardiac apoptosis in angiotensin II-induced hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 282, H1635-H1641.	1.5	54
206	ET A Receptor Mediates Altered Leukocyte-Endothelial Cell Interaction and Adhesion Molecules Expression in DOCAâ€“Salt Rats. Hypertension, 2004, 43, 872-879.	1.3	53
207	Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors. Journal of the American Society of Hypertension, 2008, 2, 165-172.	2.3	53
208	Vascular inflammation in absence of blood pressure elevation in transgenic murine model overexpressing endothelin-1 in endothelial cells. Journal of Hypertension, 2008, 26, 1102-1109.	0.3	52
209	Vascular and cardiac overexpression of endothelin-1 gene in one-kidney, one clip Goldblatt hypertensive rats but only in the late phase of two-kidney one clip Goldblatt hypertension. Journal of Hypertension, 1996, 14, 57???64.	0.3	51
210	Differential ANG II-induced growth activation pathways in mesenteric artery smooth muscle cells from SHR. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 281, H30-H39.	1.5	51
211	Mthfrdeficiency induces endothelial progenitor cell senescence via uncoupling of eNOS and downregulation of SIRT1. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H745-H753.	1.5	51
212	Innate Immunity in Hypertension. Current Hypertension Reports, 2014, 16, 413.	1.5	51
213	Aldosterone: A risk factor for vascular disease. Current Hypertension Reports, 2003, 5, 59-65.	1.5	50
214	Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to action. Journal of Human Hypertension, 2008, 22, 63-70.	1.0	50
215	The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 â€“ blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2007, 23, 529-538.	0.8	49
216	Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. Journal of Hypertension, 2009, 27, 2192-2200.	0.3	49

#	Article	IF	Citations
217	Correction of Remodeling and Function of Small Arteries in Human Hypertension by Cilazapril, an Angiotensin I-Converting Enzyme Inhibitor. Journal of Cardiovascular Pharmacology, 1996, 27, 13-18.	0.8	49
218	Vascular Endothelin-1 Gene Expression and Effect on Blood Pressure of Chronic ET A Endothelin Receptor Antagonism After Nitric Oxide Synthase Inhibition With L- NAME in Normal Rats. Circulation, 1997, 95, 240-244.	1.6	49
219	Endothelin-1 Attenuates Ï‰3 Fatty Acidâ€“Induced Apoptosis by Inhibition of Caspase 3. Hypertension, 2000, 35, 287-291.	1.3	48
220	The New ACC/AHA Hypertension Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. American Journal of Hypertension, 2018, 31, 133-135.	1.0	48
221	Role of calcium influx and intracellular calcium stores in angiotensin II-mediated calcium hyper-responsiveness in smooth muscle from spontaneously hypertensive rats. Journal of Hypertension, 1997, 15, 1431-1439.	0.3	46
222	Aldosterone-Induced Vascular Remodeling and Endothelial Dysfunction Require Functional Angiotensin Type 1a Receptors. Hypertension, 2016, 67, 897-905.	1.3	46
223	Receptors for atrial natriuretic factor in cultured vascular smooth muscle cells. Life Sciences, 1986, 38, 817-826.	2.0	45
224	Molecular Analysis of Human Prorenin Prosegment Variants in Vitro and in Vivo. Journal of Biological Chemistry, 1995, 270, 16355-16359.	1.6	45
225	Angiotensin II and Vasopressin Modulate Intracellular Free Magnesium in Vascular Smooth Muscle Cells through Na+-dependent Protein Kinase C Pathways. Journal of Biological Chemistry, 1996, 271, 24353-24358.	1.6	45
226	Endothelin A Receptor Blockade Decreases Expression of Growth Factors and Collagen and Improves Matrix Metalloproteinase-2 Activity in Kidneys from Stroke-Prone Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2002, 39, 892-900.	0.8	45
227	Vascular proinflammatory responses by aldosterone are mediated via c-Src trafficking to cholesterol-rich microdomains: role of PDGFR. Cardiovascular Research, 2011, 91, 720-731.	1.8	45
228	Angiotensin II Blockade Limits Tubular Protein Overreabsorption and the Consequent Upregulation of Endothelin 1 Gene in Experimental Membranous Nephropathy. Nephron Experimental Nephrology, 1998, 6, 121-131.	2.4	44
229	Activation of the Na+-H+Exchanger Modulates Angiotensin IIâ€“Stimulated Na+-Dependent Mg2+Transport in Vascular Smooth Muscle Cells in Genetic Hypertension. Hypertension, 1999, 34, 442-449.	1.3	44
230	How Structure, Mechanics, and Function of the Vasculature Contribute to Blood Pressure Elevation in Hypertension. Canadian Journal of Cardiology, 2020, 36, 648-658.	0.8	44
231	The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy. Canadian Journal of Cardiology, 2002, 18, 625-41.	0.8	44
232	Protective role of vascular smooth muscle cell PPARÎ³ in angiotensin II-induced vascular disease. Cardiovascular Research, 2013, 97, 562-570.	1.8	43
233	Endothelin-1 Overexpression Exaggerates Diabetes-Induced Endothelial Dysfunction by Altering Oxidative Stress. American Journal of Hypertension, 2016, 29, 1245-1251.	1.0	43
234	Resistance artery mechanics and composition in angiotensin II-infused rats. Journal of Hypertension, 2003, 21, 189-198.	0.3	42

#	Article	IF	Citations
235	Three-Month Endothelial Human Endothelin-1 Overexpression Causes Blood Pressure Elevation and Vascular and Kidney Injury. Hypertension, 2018, 71, 208-216.	1.3	42
236	Angiotensin II Regulates Vascular Smooth Muscle Cell pH, Contraction, and Growth Via Tyrosine Kinaseâ€“Dependent Signaling Pathways. Hypertension, 1997, 30, 222-229.	1.3	42
237	Inflammation and Vascular Hypertrophy Induced by Angiotensin II. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 707-709.	1.1	41
238	Long-term effects of the PPARÎ³ activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats. Canadian Journal of Physiology and Pharmacology, 2004, 82, 976-985.	0.7	41
239	Differential regulation of thioredoxin and NAD(P)H oxidase by angiotensin II in male and female mice. Journal of Hypertension, 2007, 25, 1263-1271.	0.3	41
240	Role of the endothelium in adrenergic responses of mesenteric artery rings of pregnant rats. American Journal of Obstetrics and Gynecology, 1990, 163, 229-234.	0.7	40
241	Relationship between small-artery structure and systolic, diastolic and pulse pressure in essential hypertension. Journal of Hypertension, 1999, 17, 381-387.	0.3	40
242	Small artery mechanics in hyperhomocysteinemic mice. Journal of Hypertension, 2004, 22, 959-966.	0.3	40
243	Mitogen-activated protein kinase activation by hydrogen peroxide is mediated through tyrosine kinase-dependent, protein kinase C-independent pathways in vascular smooth muscle cells: upregulation in spontaneously hypertensive rats. Journal of Hypertension, 2005, 23, 2005-2012.	0.3	40
244	Primary aldosteronism: a common cause of resistant hypertension. Cmaj, 2017, 189, E773-E778.	0.9	40
245	Cardiac Microvasculature in DOCA-Salt Hypertensive Rats. Hypertension, 1999, 34, 795-801.	1.3	39
246	Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in aldosterone-induced hypertension. Clinical Science, 2002, 103, 25S-30S.	1.8	39
247	³H-VASOPRESSIN BINDING TOTHE RAT MESENTERIC ARTERY. Endocrinology, 1983, 113, 409-411.	1.4	38
248	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 â€“ blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2008, 24, 455-463.	0.8	38
249	Vascular gene expression in mice overexpressing human endothelin-1 targeted to the endothelium. Physiological Genomics, 2011, 43, 148-160.	1.0	38
250	The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I–Blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2004, 20, 31-40.	0.8	38
251	Chronic endothelin receptor antagonist treatment of young spontaneously hypertensive rats. Journal of Hypertension, 1995, 13, 647-652.	0.3	37
252	Endothelin receptor subtypes in resistance arteries from humans and rats. Cardiovascular Research, 1995, 29, 532-535.	1.8	37

#	Article	IF	Citations
253	Effects of antihypertensive drugs on vascular remodeling: do they predict outcome in response to antihypertensive therapy?. Current Opinion in Nephrology and Hypertension, 2001, 10, 617-624.	1.0	37
254	A Call to Regulate Manufacture and Marketing of Blood Pressure Devices and Cuffs: A Position Statement From the World Hypertension League, International Society of Hypertension and Supporting Hypertension Organizations. Journal of Clinical Hypertension, 2016, 18, 378-380.	1.0	37
255	High Systolic Blood Pressure at Hospital Admission Is an Important Risk Factor in Models Predicting Outcome of COVID-19 Patients. American Journal of Hypertension, 2021, 34, 282-290.	1.0	37
256	Cytosolic Calcium Changes Induced by Angiotensin II in Neonatal Rat Atrial and Ventricular Cardiomyocytes Are Mediated via Angiotensin II Subtype 1 Receptors. Hypertension, 1996, 27, 1090-1096.	1.3	37
257	Autoradiographic visualization of the natriuretic peptide receptor-B in rat tissues. Regulatory Peptides, 1992, 39, 177-189.	1.9	36
258	Blood Pressure Control and Benefits of Antihypertensive Therapy. Hypertension, 2001, 38, 537-542.	1.3	36
259	Reduced Macrophage-Dependent Inflammation Improves Endothelin-1â€“Induced Vascular Injury. Hypertension, 2013, 62, 112-117.	1.3	36
260	Effect of Vasopressin Antagonism on Structure and Mechanics of Small Arteries and Vascular Expression of Endothelin-1 in Deoxycorticosterone Acetateâ€“Salt Hypertensive Rats. Hypertension, 1998, 32, 770-777.	1.3	35
261	Blood Pressure and Small Arteries in DOCA-Saltâ€“Treated Genetically AVP-Deficient Rats. Hypertension, 1999, 34, 907-913.	1.3	35
262	Inhibition of the renin angiotensin system: Implications for the endothelium. Current Diabetes Reports, 2006, 6, 274-278.	1.7	35
263	Effects of antihypertensive therapy on hypertensive vascular disease. Current Hypertension Reports, 2000, 2, 280-288.	1.5	34
264	Cyclic GMP Inhibits a Pharmacologically Distinct Na+/H+ Exchanger Variant in Cultured Rat Astrocytes via an Extracellular Site of Action. Journal of Neurochemistry, 2002, 68, 1451-1461.	2.1	34
265	Endocrine Conditions and COVID-19. Hormone and Metabolic Research, 2020, 52, 471-484.	0.7	34
266	Pathophysiology of smooth muscle in hypertension. Canadian Journal of Physiology and Pharmacology, 1995, 73, 574-584.	0.7	33
267	Reactive Oxygen Species and Hypertension: A Complex Association. Antioxidants and Redox Signaling, 2008, 10, 1041-1044.	2.5	33
268	Deleterious combined effects of salt-loading and endothelial cell restricted endothelin-1 overexpression on blood pressure and vascular function in mice. Journal of Hypertension, 2010, 28, 1243-1251.	0.3	33
269	Induction of Cardiac Angiogenesis Requires Killer Cell Lectin-Like Receptor 1 and Î±4Î²7 Integrin Expression by NK Cells. Journal of Immunology, 2010, 185, 7014-7025.	0.4	33
270	Inducible Human Endothelin-1 Overexpression in Endothelium Raises Blood Pressure via Endothelin Type A Receptors. Hypertension, 2015, 66, 347-355.	1.3	33

#	Article	IF	Citations
271	Role of Blood Pressure Reduction in Prevention of Cardiac and Vascular Hypertrophy. American Journal of Hypertension, 2005, 18, 922-929.	1.0	32
272	Monocyte Derivatives Promote Angiogenesis and Myocyte Survival in a Model of Myocardial Infarction. Cell Transplantation, 2010, 19, 369-386.	1.2	32
273	Interleukin-2 enhances angiogenesis and preserves cardiac function following myocardial infarction. Cytokine, 2011, 56, 732-738.	1.4	32
274	High Blood Pressure 2016: Why Prevention and Control Are Urgent and Important. The World Hypertension League, International Society of Hypertension, World Stroke Organization, International Diabetes Foundation, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Nephrology. Journal of Clinical Hypertension, 2016, 18, 714-717.	1.0	32
275	Vascular smooth muscle cell peroxisome proliferator-activated receptor Î³ protects against endothelin-1-induced oxidative stress and inflammation. Journal of Hypertension, 2017, 35, 1390-1401.	0.3	32
276	Hypertension in Canada: Past, Present, and Future. Annals of Global Health, 2018, 82, 288.	0.8	32
277	Intracellular Ca 2+ Modulation by Angiotensin II and Endothelin-1 in Cardiomyocytes and Fibroblasts From Hypertrophied Hearts of Spontaneously Hypertensive Rats. Hypertension, 1996, 28, 797-805.	1.3	32
278	Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats. Journal of Hypertension, 2005, 23, 401-409.	0.3	31
279	Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP. Journal of Hypertension, 2008, 26, 322-333.	0.3	31
280	Angiotensin II, Aldosterone, and Anti-Inflammatory Lymphocytes: Interplay and Therapeutic Opportunities. International Journal of Hypertension, 2012, 2012, 1-5.	0.5	31
281	Vascular Endothelin-1 Expression and Effect of an Endothelin ETA Antagonist on Structure and Function of Small Arteries from Stroke-Prone Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 1998, 31, S309-S312.	0.8	31
282	Endothelin-1 Gene Expression in Blood Vessels and Kidney of Spontaneously Hypertensive Rats (SHR), L-NAME-Treated SHR, and Renovascular Hypertensive Rats. Journal of Cardiovascular Pharmacology, 1998, 31, S380-S383.	0.8	31
283	Specific binding of atrial natriuretic factor to renal glomeruli in Doca- and Doca-salt-treated rats correlation with atrial and plasma levels. Biochemical and Biophysical Research Communications, 1987, 145, 522-531.	1.0	30
284	Resistance Artery Structure and Neuroeffector Mechanisms in Hypertension Induced by Inhibition of Nitric Oxide Synthase. American Journal of Hypertension, 1994, 7, 996-1004.	1.0	30
285	The Protective Effects of Angiotensin II Blockade with Olmesartan Medoxomil on Resistance Vessel Remodeling (The VIOS study). American Journal of Cardiovascular Drugs, 2006, 6, 335-342.	1.0	30
286	Role of T Regulatory Lymphocytes in the Pathogenesis of High-Fructose Dietâ€“Induced Metabolic Syndrome. Hypertension, 2013, 61, 1316-1321.	1.3	30
287	Activation of the Cardiac Reninâ€“Angiotensin System in High Oxygen-Exposed Newborn Rats. Hypertension, 2016, 67, 774-782.	1.3	30
288	Aberrant Adenylyl Cyclase/cAMP Signal Transduction and G Protein Levels in Platelets From Hypertensive Patients Improve With Antihypertensive Drug Therapy. Hypertension, 1996, 28, 83-90.	1.3	30

#	Article	IF	Citations
289	Immune System and Microvascular Remodeling in Humans. Hypertension, 2022, 79, 691-705.	1.3	30
290	The effect of angiotensin II on platelet intracellular free magnesium and calcium ionic concentrations in essential hypertension. Journal of Hypertension, 1993, 11, 551-558.	0.3	29
291	Attenuated Responses to Angiotensin II in Follitropin Receptor Knockout Mice, a Model of Menopause-Associated Hypertension. Hypertension, 2003, 42, 761-767.	1.3	29
292	Synergistic vascular protective effects of combined low doses of PPARÎ± and PPARÎ³ activators in angiotensin II-induced hypertension in rats. British Journal of Pharmacology, 2007, 151, 45-53.	2.7	29
293	SPRINT Proves that Lower Is Better for Nondiabetic High-Risk Patients, but at a Price. American Journal of Hypertension, 2016, 29, 2-4.	1.0	29
294	Innate and Innate-Like Immune System in Hypertension and Vascular Injury. Current Hypertension Reports, 2019, 21, 4.	1.5	29
295	Endothelin: Role in Experimental Hypertension. Journal of Cardiovascular Pharmacology, 2000, 35, S33-S35.	0.8	29
296	Effect of Antihypertensive Treatment on Response to Endothelin of Resistance Arteries of Hypertensive Rats. Journal of Cardiovascular Pharmacology, 1993, 21, 725-731.	0.8	28
297	Expression of endothelin-1 gene in blood vessels of adult spontaneously hypertensive rats. Life Sciences, 1995, 56, 1889-1896.	2.0	28
298	Effect of antihypertensive treatment and N?? -nitro-L-arginine methyl ester on cardiovascular structure in deoxycorticosterone acetate-salt hypertensive rats. Journal of Hypertension, 1996, 14, 1331-1339.	0.3	28
299	Mechanical properties of mesenteric resistance arteries from Dahl salt-resistant and salt-sensitive rats. Journal of Hypertension, 1998, 16, 1907-1912.	0.3	28
300	Small Artery Remodeling in Hypertension: Can It Be Corrected?. American Journal of the Medical Sciences, 2001, 322, 7-11.	0.4	28
301	Effect of antihypertensive treatment on small artery remodeling in hypertension. Canadian Journal of Physiology and Pharmacology, 2003, 81, 168-176.	0.7	28
302	Disparate Effects of Carvedilol Versus Metoprolol Treatment of Stroke-Prone Spontaneously Hypertensive Rats on Endothelial Function of Resistance Arteries. Journal of Cardiovascular Pharmacology, 2000, 35, 763-768.	0.8	28
303	Mechanisms of remodelling of small arteries, antihypertensive therapy and the immune system in hypertension. Clinical and Investigative Medicine, 2015, 38, 394.	0.3	28
304	Contractile responses and signal transduction of endothelin-1 in aorta and mesenteric vasculature of adult spontaneously hypertensive rats. Canadian Journal of Physiology and Pharmacology, 1993, 71, 473-483.	0.7	27
305	Endothelin-1 expression in blood vessels of DOCA-salt hypertensive rats treated with the combined ET_A/ET_B endothelin receptor antagonist bosentan. Canadian Journal of Physiology and Pharmacology, 1995, 73, 390-398.	0.7	27
306	Vascular Remodeling and Endothelial Function in Hypertensive Patients: Effects of Antihypertensive Therapy. Scandinavian Cardiovascular Journal, 1998, 32, 15-21.	0.4	27

#	Article	IF	Citations
307	Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats. Journal of Hypertension, 2002, 20, 899-907.	0.3	27
308	Role of the actin cytoskeleton in angiotensin II signaling in human vascular smooth muscle cells. Canadian Journal of Physiology and Pharmacology, 2005, 83, 91-97.	0.7	27
309	Hypertension Management in Patients with Renal Cell Cancer Treated with Anti-Angiogenic Agents. Current Oncology, 2012, 19, 202-208.	0.9	27
310	Effects of Recombinant Human Erythropoietin on Resistance Artery Endothelial Function in Stage 4 Chronic Kidney Disease. Journal of the American Heart Association, 2013, 2, e000128.	1.6	27
311	Endothelin Subtype B Receptorâ€"Mediated Calcium and Contractile Responses in Small Arteries of Hypertensive Rats. Hypertension, 1995, 26, 1041-1045.	1.3	27
312	Vascular binding sites and biological activity of vasopressin in DOCA-salt hypertensive rats. Journal of Hypertension, 1988, 6, 211-217.	0.3	26
313	Tissue Targeting of Angiotensin Peptides. Journal of Biological Chemistry, 1997, 272, 12994-12999.	1.6	26
314	The World Hypertension League and International Society of Hypertension Call on Governments, Nongovernmental Organizations, and the Food Industry to Work to Reduce Dietary Sodium. Journal of Clinical Hypertension, 2014, 16, 99-100.	1.0	26
315	Comparison of Effect of Endothelin Antagonism and Angiotensin-Converting Enzyme Inhibition on Blood Pressure and Vascular Structure in Spontaneously Hypertensive Rats Treated With N Ï‰ -Nitro- l -Arginine Methyl Ester. Hypertension, 1996, 28, 188-195.	1.3	26
316	Atrial natriuretic peptide inhibits the effect of endogenous angiotensin II on plasma aldosterone in conscious sodium-depleted rats. Clinical Science, 1987, 72, 31-35.	1.8	25
317	Receptors for Arg8-vasopressin, angiotensin II, and atrial natriuretic peptide in the mesenteric vasculature of pregnant rats. Canadian Journal of Physiology and Pharmacology, 1991, 69, 137-144.	0.7	25
318	Increased inflammatory biomarkers in hypertensive type 2 diabetic patients: improvement after angiotensin II type 1 receptor blockade. Journal of the American Society of Hypertension, 2007, 1, 189-199.	2.3	25
319	Vascular Effects of Antihypertensive Drug Therapy. Current Hypertension Reports, 2010, 12, 226-232.	1.5	25
320	Inactivation of endothelial proprotein convertase 5/6 decreases collagen deposition in the cardiovascular system: role of fibroblast autophagy. Journal of Molecular Medicine, 2011, 89, 1103-1111.	1.7	25
321	Human and murine memory Î³Î´ T cells: Evidence for acquired immune memory in bacterial and viral infections and autoimmunity. Cellular Immunology, 2020, 357, 104217.	1.4	25
322	Growth Factors Mediate Intracellular Signaling in Vascular Smooth Muscle Cells Through Protein Kinase Câ€"Linked Pathways. Hypertension, 1997, 30, 1440-1447.	1.3	25
323	The 2001 Canadian recommendations for the management of hypertension: Part one--Assessment for diagnosis, cardiovascular risk, causes and lifestyle modification. Canadian Journal of Cardiology, 2002, 18, 604-24.	0.8	25
324	Hypertensive eye disease. Nature Reviews Disease Primers, 2022, 8, 14.	18.1	25

#	Article	IF	Citations
325	Circulatory therapeutics: use of antihypertensive agents and their effects on the vasculature. Journal of Cellular and Molecular Medicine, 2010, 14, 1018-29.	1.6	24
326	Erythropoietin-induced hypertension and vascular injury in mice overexpressing human endothelin-1. Journal of Hypertension, 2014, 32, 784-794.	0.3	24
327	Recommendations for Intensive Blood Pressure Lowering in High-Risk Patients, the Canadian Viewpoint. Hypertension, 2016, 68, 3-5.	1.3	24
328	Reduction of C-reactive protein and the use of anti-hypertensives. Vascular Health and Risk Management, 2007, 3, 975-83.	1.0	24
329	Vascular structure in NG-nitro-L-arginine methyl ester-induced hypertension: methodological considerations for studies of small arteries in hypertension. Journal of Hypertension, 1995, 13, 817-821.	0.3	23
330	PPAR Activation: A New Target for the Treatment of Hypertension. Journal of Cardiovascular Pharmacology, 2007, 50, 120-125.	0.8	23
331	Potentiation of vascular oxidative stress and nitric oxide-mediated endothelial dysfunction by high-fat diet in a mouse model of estrogen deficiency and hyperandrogenemia. Journal of the American Society of Hypertension, 2009, 3, 295-305.	2.3	23
332	Role of endothelins in animal models of hypertension: focus on cardiovascular protection. Canadian Journal of Physiology and Pharmacology, 2003, 81, 511-521.	0.7	22
333	Immune Modulation of Resistance Artery Remodelling. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 70-72.	1.2	22
334	Inflammation, immunity and development of essential hypertension. Journal of Hypertension, 2014, 32, 228-229.	0.3	22
335	Global Impact of the 2017 American College of Cardiology/American Heart Association Hypertension Guidelines. Circulation, 2018, 137, 883-885.	1.6	22
336	Orthostatic Hypotension: A Posture-Induced Hyperdopaminergic State. American Journal of the Medical Sciences, 1985, 289, 3-11.	0.4	21
337	Role of Angiotensin Type-1 and Angiotensin Type-2 Receptors in the Expression of Vascular Integrins in Angiotensin IIâ€“Infused Rats. Hypertension, 2006, 47, 122-127.	1.3	21
338	miR-431-5p Knockdown Protects Against Angiotensin IIâ€“Induced Hypertension and Vascular Injury. Hypertension, 2019, 73, 1007-1017.	1.3	21
339	Intracellular signal transduction for vasoactive peptides in hypertension. Canadian Journal of Physiology and Pharmacology, 1994, 72, 954-962.	0.7	20
340	Improving Hypertension Outcome Measurement in Low- and Middle-Income Countries. Hypertension, 2019, 73, 990-997.	1.3	20
341	The Many Targets of Aldosterone. Hypertension, 2004, 43, 938-940.	1.3	19
342	Blood Pressure Lowering in PROGRESS (Perindopril Protection Against Recurrent Stroke Study) and White Matter Hyperintensities. Circulation, 2005, 112, 1525-1526.	1.6	19

#	Article	IF	Citations
343	Control Rates of Hypertension in North America. Hypertension, 2010, 56, 571-572.	1.3	19
344	2016 Dietary Salt Fact Sheet and Call to Action: The World Hypertension League, International Society of Hypertension, and the International Council of Cardiovascular Prevention and Rehabilitation. Journal of Clinical Hypertension, 2016, 18, 1082-1085.	1.0	19
345	CD4 ⁺ Regulatory T Lymphocytes Prevent Impaired Cerebral Blood Flow in Angiotensin IIâ€Induced Hypertension. Journal of the American Heart Association, 2019, 8, e009372.	1.6	19
346	Role of interleukin-23/interleukin-17 axis in T-cell-mediated actions in hypertension. Cardiovascular Research, 2021, 117, 1274-1283.	1.8	19
347	Effect of enalapril (MK-421), an orally active angiotensin I converting enzyme inhibitor, on blood pressure, active and inactive plasma renin, urinary prostaglandin E2, and kallikrein excretion in conscious rats. Canadian Journal of Physiology and Pharmacology, 1984, 62, 116-123.	0.7	18
348	Vasopressin receptors and inositol trisphosphate production in blood vessels of spontaneously hypertensive rats. Canadian Journal of Physiology and Pharmacology, 1989, 67, 232-239.	0.7	18
349	Expression of Cell Cycle Proteins in Blood Vessels of Angiotensin IIâ€“Infused Rats. Hypertension, 2001, 37, 604-608.	1.3	18
350	The vascular phenotypes in hypertension: Relation with the natural history of hypertension. Journal of the American Society of Hypertension, 2007, 1, 56-67.	2.3	18
351	Cardiac hypertrophy is associated with altered thioredoxin and ASK-1 signaling in a mouse model of menopause. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H1481-H1488.	1.5	18
352	Resistant Hypertension: An Update. American Journal of Hypertension, 2019, 32, 1-3.	1.0	18
353	Circulating let-7g-5p and miR-191-5p Are Independent Predictors of Chronic Kidney Disease in Hypertensive Patients. American Journal of Hypertension, 2020, 33, 505-513.	1.0	18
354	Biological action and binding sites for vasopressin on the meseteric artery from normal and sodium-depleted rats. Life Sciences, 1984, 35, 1489-1495.	2.0	17
355	Platelet binding sites and plasma concentration of atrial natriuretic peptide in patients with essential hypertension. Journal of Hypertension, 1988, 6, 565-572.	0.3	17
356	Atrial natriuretic factor: specific binding to renal glomeruli during the development of two-kidney, one clip hypertension in the rat. Journal of Hypertension, 1988, 6, 587-592.	0.3	17
357	Effect of Short-Term Treatment of SHR With the Novel Calcium Channel Antagonist Mibefradil on Function of Small Arteries. American Journal of Hypertension, 1997, 10, 94-100.	1.0	17
358	Endothelin-A-Receptor Blockade Improves Renal Function and Doubles the Lifespan of Stroke-Prone Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2000, 36, S300-S304.	0.8	17
359	Altered Cardiac Endothelin Receptors and Protein Kinase C in Deoxycorticosterone-Salt Hypertensive Rats. Journal of Molecular and Cellular Cardiology, 2000, 32, 665-676.	0.9	17
360	Racial disparities in cardiovascular risk factors among diagnosed hypertensive subjects. Journal of the American Society of Hypertension, 2011, 5, 239-248.	2.3	17

#	Article	IF	Citations
361	Enhanced Expression of Endothelin-1 Gene May Cause Blood Pressure-Independent Vascular Hypertrophy. Journal of Cardiovascular Pharmacology, 1995, 26, S5-8.	0.8	17
362	The Future of Clinical Trials in Chronic Renal Disease: Outcome of an NIH/FDA/Physician Specialist Conference. Journal of Clinical Pharmacology, 2000, 40, 815-825.	1.0	16
363	Effects of PPAR-Î³ Knock-down and Hyperglycemia on Insulin Signaling in Vascular Smooth Muscle Cells From Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2007, 49, 346-354.	0.8	16
364	Peroxisome proliferator-activated receptors and the vascular system: beyond their metabolic effects. Journal of the American Society of Hypertension, 2008, 2, 227-238.	2.3	16
365	Erratum to â€œAngiotensin II, Aldosterone, and Anti-Inflammatory Lymphocytes: Interplay and Therapeutic Opportunitiesâ€. International Journal of Hypertension, 2012, 2012, 1-3.	0.5	16
366	Is It Time to Reappraise Blood Pressure Thresholds and Targets?. Hypertension, 2016, 68, 266-268.	1.3	16
367	Do We Need a New Definition of Hypertension After SPRINT?. American Journal of Hypertension, 2016, 29, 1127-1129.	1.0	16
368	Antiproliferative effect of L-NAME on rat vascular smooth muscle cells. Life Sciences, 2000, 67, 1613-1623.	2.0	15
369	Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats. American Journal of Hypertension, 2003, 16, 931-937.	1.0	15
370	Cardiac Type-1 Angiotensin II Receptor Status in Deoxycorticosterone Acetateâ€“Salt Hypertension in Rats. Hypertension, 1997, 30, 1253-1259.	1.3	15
371	Calcium dependence of effects of endothelin on rat mesenteric microvessels. Canadian Journal of Physiology and Pharmacology, 1991, 69, 798-804.	0.7	14
372	Blunted inhibition by insulin of agonist-stimulated calcium, pH and aggregatory responses in platelets from hypertensive patients. Journal of Hypertension, 1994, 12, 1255???1264.	0.3	14
373	Remodeling of Resistance Arteries in Human Hypertension: Effects of Cilazapril, an Angiotensin- I -Converting Enzyme Inhibitor. Cardiology, 1995, 86, 16-22.	0.6	14
374	Endothelin influences pHi of human platelets through protein kinase C mediated pathways. Thrombosis Research, 1995, 78, 55-65.	0.8	14
375	Significance of recently identified peptides in hypertension: endothelin, natriuretic peptides, adrenomedullin, leptin. Medical Clinics of North America, 2004, 88, 39-62.	1.1	14
376	Inhibitory effects of PPAR-Î³ on endothelin-1-induced inflammatory pathways in vascular smooth muscle cells from normotensive and hypertensive rats. Journal of the American Society of Hypertension, 2007, 1, 150-160.	2.3	14
377	Countervailing vascular effects of rosiglitazone in high cardiovascular risk mice: role of oxidative stress and PRMT-1. Clinical Science, 2010, 118, 583-592.	1.8	14
378	What Is the Ideal Blood Pressure Goal for Patients with Diabetes Mellitus and Nephropathy?. Current Cardiology Reports, 2012, 14, 651-659.	1.3	14

#	Article	IF	Citations
379	Periodontitis and hypertension: causally linked by immune mechanisms. European Heart Journal, 2019, 40, 3471-3473.	1.0	14
380	Endothelin in hypertension. Current Opinion in Cardiology, 1995, 10, 493-494.	0.8	13
381	Vascular smooth muscle growth and extracellular matrix deposition: is there a role for the sympathetic nervous system?. Journal of Hypertension, 2002, 20, 179-181.	0.3	13
382	The angiotensin???endothelin relationship. Journal of Hypertension, 2003, 21, 2245-2247.	0.3	13
383	Endothelin???aldosterone interaction and proteinuria in low-renin hypertension. Journal of Hypertension, 2004, 22, 573-582.	0.3	13
384	Inhibition of the reninâ€“angiotensin system for lowering coronary artery disease risk. Current Opinion in Pharmacology, 2013, 13, 274-279.	1.7	13
385	Preservation of Endothelium-Dependent Relaxation in Atherosclerotic Mice with Endothelium-Restricted Endothelin-1 Overexpression. Journal of Pharmacology and Experimental Therapeutics, 2013, 347, 30-37.	1.3	13
386	The International Society of Hypertension and World Hypertension League call on governments, nongovernmental organizations and the food industry to work to reduce dietary sodium. Journal of Hypertension, 2014, 32, 446-447.	0.3	13
387	Does Endothelin-1 Raise or Lower Blood Pressure in Humans?. Nephron, 2018, 139, 47-50.	0.9	13
388	Increased blood pressure, vascular inflammation, and endothelial dysfunction in androgen-deficient follitropin receptor knockout male mice. Journal of the American Society of Hypertension, 2007, 1, 353-361.	2.3	12
389	The Flame That Lights the Fire. Hypertension, 2008, 52, 205-206.	1.3	12
390	Expertise. Journal of Hypertension, 2017, 35, 1564-1566.	0.3	12
391	Novel mechanisms of hypertension and vascular dysfunction. Nature Reviews Nephrology, 2018, 14, 73-74.	4.1	12
392	Endothelium-restricted endothelin-1 overexpression in type 1 diabetes worsens atherosclerosis and immune cell infiltration via NOX1. Cardiovascular Research, 2021, 117, 1144-1153.	1.8	12
393	Effects of monovalent and divalent cations and of guanine nucleotides on binding of vasopressin to the rat mesenteric vasculature. Canadian Journal of Physiology and Pharmacology, 1987, 65, 1171-1181.	0.7	11
394	Vascular receptors for angiotensin, vasopressin, and atrial natriuretic peptide in experimental hypertension. Canadian Journal of Physiology and Pharmacology, 1989, 67, 1118-1123.	0.7	11
395	Renal Effects of Immersion in Essential Hypertension. American Journal of Hypertension, 1994, 7, 120-128.	1.0	11
396	ENDOTHELIN-1 GENE EXPRESSION AND VASCULAR HYPERTROPHY IN DOCA-SALT HYPERTENSION COMPARED TO SPONTANEOUSLY HYPERTENSIVE RATS. Clinical and Experimental Pharmacology and Physiology, 1995, 22, S188-S190.	0.9	11

#	Article	IF	Citations
397	SAM68: a downstream target of angiotensin II signaling in vascular smooth muscle cells in genetic hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 286, H1954-H1962.	1.5	11
398	Angiotensin II induces vascular dysfunction without exacerbating blood pressure elevation in a mouse model of menopause-associated hypertension. Journal of Hypertension, 2006, 24, 1365-1373.	0.3	11
399	Vasorelaxant effects of and receptors for atrial natriuretic peptides in the mesenteric artery and aorta of the rat. Canadian Journal of Physiology and Pharmacology, 1988, 66, 951-956.	0.7	10
400	Solubilization and Molecular Characterization of the Atrial Natriuretic Peptide (ANP) Receptor in Human Platelets: Comparison with ANP Receptors in Rat Tissues*. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 484-491.	1.8	10
401	Immune mechanisms in hypertension. Journal of Hypertension, 2013, 31, 1944-1945.	0.3	10
402	CXCL1â€“CXCR2 lead monocytes to the heart of the matter. European Heart Journal, 2018, 39, 1832-1834.	1.0	10
403	Sex Differences in the Immune System in Relation to Hypertension and Vascular Disease. Canadian Journal of Cardiology, 2022, 38, 1828-1843.	0.8	10
404	Reduction of Hypertension in One-Kidney One-Clip Rabbits by Immunization with Tonin. Experimental Biology and Medicine, 1979, 162, 245-248.	1.1	9
405	Endothelial receptor subtypes in mesenteric wascular smooth muscle cells of spontaneously hypertensiwe rats. Canadian Journal of Physiology and Pharmacology, 1995, 73, 1262-1273.	0.7	9
406	Differential effects of vasopressin and endothelin-1 on vascular contractile and calcium responses in pressurized small arteries from spontaneously hypertensive rats. Journal of Hypertension, 1996, 14, 983???992.	0.3	9
407	Structure and Function of Small Arteries of Essential Hypertensive Patients Following Chronic Treatment with Once-a-Day Nifedipine. Cardiology, 1997, 88, 20-26.	0.6	9
408	Calcium, Magnesium, and Oxidative Stress in Hyperaldosteronism. Circulation, 2005, 111, 830-831.	1.6	9
409	A Novel and Simplified Method of Culture of Human Blood-Derived Early Endothelial Progenitor Cells for the Treatment of Ischemic Vascular Disease. Cell Transplantation, 2011, 20, 1431-1443.	1.2	9
410	Hypertension Guidelines in the United States and Canada: Are We Getting Closer?. Hypertension, 2018, 71, 976-978.	1.3	9
411	Overproduction of endothelin-1 impairs glucose tolerance but does not promote visceral adipose tissue inflammation or limit metabolic adaptations to exercise. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E548-E558.	1.8	9
412	Hypertension and COVID-19: Updates from the era of vaccines and variants. Journal of Clinical and Translational Endocrinology, 2022, 27, 100285.	1.0	9
413	Comparative biological activities of ANF (Arg 101 - Tyr 126) and the synthetic form of circulating ANF (Ser 99 - Tyr 126). Biochemical and Biophysical Research Communications, 1986, 135, 987-993.	1.0	8
414	Blood Pressure Effects of Angiotensin II and Vasopressin in Conscious Pregnant Normotensive and Spontaneously Hypertensive Rats. Clinical and Experimental Hypertension Part B, Hypertension in Pregnancy, 1986, 5, 135-158.	0.2	8

#	Article	IF	Citations
415	Effect of a chronic infusion of atrial natriuretic factor on glomerular and vascular receptors in spontaneously hypertensive rats. Journal of Hypertension, 1989, 7, 335???342.	0.3	8
416	ETAAND ETBRECEPTORS ON VASCULAR SMOOTH MUSCLE CELLS FROM MESENTERIC VESSELS OF SPONTANEOUSLY HYPERTENSIVE RATS. Clinical and Experimental Pharmacology and Physiology, 1995, 22, S193-S194.	0.9	8
417	Novel Drugs Targeting Hypertension: Renin Inhibitors and Beyond. Journal of Cardiovascular Pharmacology, 2007, 50, 3-8.	0.8	8
418	Reviewing the future of renin-angiotensin system blockade: The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the prevention of atrial fibrillation. Canadian Journal of Cardiology, 2010, 26, 21E-23E.	0.8	8
419	Hypertension: treatments, diabetes, and developing regions. Lancet, The, 2012, 380, 539-541.	6.3	8
420	Chronic Elevation of Endothelin-1 Alone May Not Be Sufficient to Impair Endothelium-Dependent Relaxation. Hypertension, 2019, 74, 1409-1419.	1.3	8
421	In vivo heterologous regulation of rat glomerular and vascular atrial natriuretic factor receptors by angiotensin II. Journal of Hypertension, 1990, 8, 1077-1083.	0.3	7
422	Progress in secondary prevention of stroke with PROGRESS. Current Hypertension Reports, 2002, 4, 39-40.	1.5	7
423	Title is missing!. American Journal of Hypertension, 2004, 17, 597-603.	1.0	7
424	Isolation of Immune Cells for Adoptive Transfer. Methods in Molecular Biology, 2017, 1527, 321-344.	0.4	7
425	Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension. Journal of Hypertension, 2019, 37, 2216-2224.	0.3	7
426	A Compendium on Hypertension. Circulation Research, 2021, 128, 803-807.	2.0	7
427	Endothelin-1 and Vasopressin Signalling in Blood Vessels of Young SHR in Comparison to Adult SHR.. Hypertension Research, 1996, 19, 121-132.	1.5	7
428	Heart Rate Reflex Responses during Gestation in Normotensive and Spontaneously Hypertensive Rats following Angiotensin II and Vasopressin. Experimental Biology and Medicine, 1987, 186, 294-298.	1.1	6
429	Endothelin-A-Receptor Blockade Improves Renal Function and Doubles the Lifespan of Stroke-Prone Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2000, 36, S300-S304.	0.8	6
430	Low birth weight and insulin resistance: can capillary recruitment predict hypertension development?. Journal of Hypertension, 2002, 20, 1933-1935.	0.3	6
431	New Twist to the Role of the Renin-Angiotensin System in Heart Failure. Hypertension, 2008, 51, 622-623.	1.3	6
432	Media-to-lumen ratio as predictor of renal abnormalities in hypertension: new findings, new questions. Journal of Hypertension, 2010, 28, 1811-1813.	0.3	6

#	Article	IF	Citations
433	International Society of Hypertension Low and Middle Income Countries Committee. Journal of Hypertension, 2010, 28, 635-636.	0.3	6
434	Hypertension Prevalence and Control: Impact of Method of Blood Pressure Measurement. Current Cardiovascular Risk Reports, 2012, 6, 267-273.	0.8	6
435	Aldosterone contributes to hypertension in male mice inducibly overexpressing human endothelin-1 in endothelium. Journal of Hypertension, 2021, 39, 1908-1917.	0.3	6
436	Basal and Angiotensin IIâ€“Induced Cytosolic Free Calcium in Adult Rat Cardiomyocytes and Fibroblasts After Volume Overload. Hypertension, 1995, 26, 1149-1153.	1.3	6
437	The angiotensin-endothelin relationship: does it play a role in cardiovascular and renal pathophysiology?. Journal of Hypertension, 2003, 21, 2245-7.	0.3	6
438	Review: ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2003, 4, 74-79.	1.0	5
439	A New Look At the Mosaic Theory of Hypertension. Canadian Journal of Cardiology, 2020, 36, 591-592.	0.8	5
440	Scoping review of COVID-19-related systematic reviews and meta-analyses: can we really have confidence in their results?. Postgraduate Medical Journal, 2022, 98, 372-379.	0.9	5
441	Endothelin-1 Signaling is Altered in Cardiac Cells from Deoxycorticosterone Acetate-Salt Hypertensive Rats. Journal of Cardiovascular Pharmacology, 1998, 31, S179-S181.	0.8	5
442	Regulation of receptors for atrial natriuretic peptide in the rat and human. Cardiovascular Drugs and Therapy, 1988, 2, 493-500.	1.3	4
443	Clinical Relationships of Cyclic GMP. Advances in Pharmacology, 1994, 26, 305-319.	1.2	4
444	Tyrosine Kinase Inhibition Attenuates Vasopressin-induced Contraction of Mesenteric Resistance Arteries: Alterations in Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2002, 40, 123-132.	0.8	4
445	MEthods of ASsessing blood pressUre: identifying thReshold and target valuEs (MeasureBP): A Review & Study Protocol. Current Hypertension Reports, 2015, 17, 533.	1.5	4
446	Expertise: No Longer a Sine Qua Non for Guideline Authors?. Hypertension, 2017, 70, 235-237.	1.3	4
447	Effects Of Endothelin-1 On Intracellular Tetrahydrobiopterin Levels In Vascular Tissue. Scandinavian Cardiovascular Journal, 2018, 52, 163-169.	0.4	4
448	New blood pressure cut-offs, prevalence of hypertension and control, and mood disorders: are patients benefitting from lower cut-offs for defining hypertension?. European Heart Journal, 2019, 40, 739-742.	1.0	4
449	Renin-Angiotensin-Aldosterone System and Pathobiology of Hypertension. , 2009, , 35-57.		4
450	Vascular Effects of Bradykinin and Sodium Nitroprusside During Pregnancy in the Rat. Clinical and Experimental Hypertension Part B, Hypertension in Pregnancy, 1989, 8, 561-582.	0.2	3

#	Article	IF	Citations
451	Inositol phosphate production in response to [Arg8]vasopressin, endothelin 1, and prostaglandin F2Î± in rat aorta and mesenteric arteries. Canadian Journal of Physiology and Pharmacology, 1992, 70, 1408-1416.	0.7	3
452	Vascular Mineralocorticoid Receptors Regulate Blood Pressure Effects on Myogenic Tone and Role in Aging. Circulation Research, 2013, 112, 415-417.	2.0	3
453	An Unusual Cause of Mineralocorticoid Hypertension. Hypertension, 2014, 64, 689-692.	1.3	3
454	Renovascular Hypertension. Hypertension, 2014, 64, 1165-1168.	1.3	3
455	The Potential Role of Primary Care in Case Detection/Screening of Primary Aldosteronism. American Journal of Hypertension, 2017, 30, 1147-1150.	1.0	3
456	A call to action to implement prescribing authority to pharmacists for hypertension management. Canadian Pharmacists Journal, 2019, 152, 285-287.	0.4	3
457	Chromosome 2 Fragment Substitutions in Dahl Salt-Sensitive Rats and RNA Sequencing Identified Enpep and Hs2st1 as Vascular Inflammatory Modulators. Hypertension, 2021, 77, 178-189.	1.3	3
458	More Evidence of Cardiorenal Protective Effects of Peroxisome Proliferator-Activated Receptor Activation. Hypertension, 2005, 46, 267-268.	1.3	2
459	Renal Denervation Therapy for Resistant Hypertension. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 350.	0.4	2
460	Mechanical Stress and the Arterial Wall. , 2014, , 97-106.		2
461	Optimum Blood Pressure Target After Lacunar Stroke. Hypertension, 2014, 63, 923-924.	1.3	2
462	A Message From the New Editorial Team at the American Journal of Hypertension. American Journal of Hypertension, 2016, 29, 1-1.	1.0	2
463	Generation of a Mouse Model with Smooth Muscle Cell Specific Loss of the Expression of PPARÎ³. Methods in Molecular Biology, 2017, 1527, 381-407.	0.4	2
464	Response to â€œCOVID-19 and ACEI/ARB: Not Associated?â€• American Journal of Hypertension, 2020, 33, 789-790.	1.0	2
465	Automated Detection and Diameter Estimation for Mouse Mesenteric Artery Using Semantic Segmentation. Journal of Vascular Research, 2021, 58, 379-387.	0.6	2
466	Oxidative Stress in Arterial Hypertension: Oxidative Stress and Hypertension. , 2008, , 51-78.		2
467	OUP accepted manuscript. American Journal of Hypertension, 2020, 33, 889.	1.0	2
468	Distinct transcriptomic profile of small arteries of hypertensive patients with chronic kidney disease identified miR-338-3p targeting GPX3 and PTPRS. Journal of Hypertension, 2022, 40, 1394-1405.	0.3	2

#	Article	IF	Citations
469	Role of the pituitary in the effects of tonin on adrenal secretion of the rat. Canadian Journal of Physiology and Pharmacology, 1983, 61, 201-206.	0.7	1
470	Atrial natriuretic peptide interferes with calcium requirements in vascular tissues of the rat. Canadian Journal of Physiology and Pharmacology, 1988, 66, 963-966.	0.7	1
471	Author??s reply. Journal of Hypertension, 1995, 13, 1220.	0.3	1
472	Hope gives reason for hope. Current Hypertension Reports, 2000, 2, 59-61.	1.5	1
473	Radioligand Binding Assay. , 2001, 51, 305-314.		1
474	Angiotensin Type 2 Receptors in the Cardiovascular System. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 63-68.	1.0	1
475	The Endothelin System. , 2007, , 317-323.		1
476	Jacques de Champlain, MD, PhD, FAHA. Hypertension, 2009, 54, 689-689.	1.3	1
477	Suppression of Peroxisome Proliferator-Activated Receptor-Î³ Activity by Angiotensin II in Vascular Smooth Muscle Involves Bcr Kinase. Circulation Research, 2009, 104, 4-6.	2.0	1
478	The Endothelin System. , 2012, , 135-139.		1
479	Reply. Journal of the American College of Cardiology, 2013, 62, 2030.	1.2	1
480	Rare Cause of Severe Hypertension in a Young Woman. Hypertension, 2015, 65, 21-24.	1.3	1
481	PS 07-28 GAMMA/DELTA T CELLS MEDIATE ANGIOTENSIN II-INDUCED HYPERTENSION AND VASCULAR INJURY. Journal of Hypertension, 2016, 34, e290.	0.3	1
482	LBPS 01-03 ENDOTHELIN-1 OVEREXPRESSION EXAGGERATES DIABETES-INDUCED ENDOTHELIAL DYSFUNCTION BY ALTERING OXIDATIVE STRESS BALANCE. Journal of Hypertension, 2016, 34, e174.	0.3	1
483	The Year in Clinical Hypertension From Other Pages. American Journal of Hypertension, 2018, 31, 136-138.	1.0	1
484	Oestrogen receptors and T cells determine how sex affects aldosterone-induced hypertension. Cardiovascular Research, 2021, 117, 655-657.	1.8	1
485	From the Editor-in-Chief: Issue at a Glance. American Journal of Hypertension, 2021, 34, 301-303.	1.0	1
486	From the Editor-in-Chief: Issue at a Glance. American Journal of Hypertension, 2021, 34, 777-778.	1.0	1

#	Article	IF	Citations
487	Vascular Changes in the Microcirculation: Arterial Remodeling and Capillary Rarefaction. , 2015, , 69-79.		1
488	Reactive Oxygen Species in Hypertension and Atherosclerosis. , 2014, , 1239-1254.		1
489	At1 Angiotensin Receptor Blockade and Angiotensin Converting Enzyme Inhibition: Effects on Vascular Remodeling and Endothelial Dysfunction in Shr. Progress in Experimental Cardiology, 1998, , 33-40.	0.0	1
490	Abstract 485: Transglutaminase 2 is a Regulator of Angiotensin II-induced ERK1/2 Activation in Vascular Smooth Muscle Cells.. Hypertension, 2012, 60, .	1.3	1
491	Vascular receptors for atrial natriuretic peptide in hypertension. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1990, 17, 673-676.	0.3	0
492	Measurement of Phospholipase D Activation in Vascular Smooth Muscle Cells. , 2001, 51, 355-362.		0
493	Guest Editorâ€™s Letter. Hypertension, 2001, 38, 535-536.	1.3	0
494	Good news for patients with type 2 diabetes: angiotensin receptor blocker treatment delays progression of diabetic nephropathy. Current Opinion in Nephrology and Hypertension, 2002, 11, 173-175.	1.0	0
495	Natriuretic Peptides as a Diagnostic and Therapeutic Tool in Cardiovascular Disease. High Blood Pressure and Cardiovascular Prevention, 2003, 10, 105-110.	1.0	0
496	The Renin-Angiotensin System, Capri 2005. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 91-108.	1.0	0
497	Response to Are the Eutrophic Effects of Angiotensin Receptor Blockers Real?. Hypertension, 2006, 48, .	1.3	0
498	Response to Aldosterone and Large Arteries. Hypertension, 2006, 47, .	1.3	0
499	How Are Stressed Prehypertensive Rats Pressured?. Hypertension, 2010, 56, 191-192.	1.3	0
500	Effect of treatment on cardiac small resistance arteries in hypertension and diabetes. Journal of Hypertension, 2012, 30, 271-272.	0.3	0
501	Arterial Hypertension. , 2012, , 1311-1319.		0
502	SP 02-5 DO WE NEED A NEW DEFINITION OF HYPERTENSION?. Journal of Hypertension, 2016, 34, e194.	0.3	0
503	PS 16-31 ENDOTHELIN-1 EXAGGERATES TYPE-1 DIABETES-ACCELERATED ATHEROSCLEROSIS THROUGH NADPH OXIDASES 1 AND 4. Journal of Hypertension, 2016, 34, e473.	0.3	0
504	SY 01-1 ADAPTATION OF MAJOR GUIDELINES FOR REGIONAL APPLICATIONS. Journal of Hypertension, 2016, 34, e12.	0.3	0

#	Article	IF	Citations
505	MPS 01-01 A CONSERVED microRNA CLUSTER AS A POTENTIAL MASTER GENE EXPRESSION REGULATOR IN ANGIOTENSIN II-INDUCED VASCULAR DAMAGE. Journal of Hypertension, 2016, 34, e78.	0.3	0
506	OS 15-02 MATRIX METALLOPROTEINASE 2 KNOCKOUT PROTECTS FROM ANGIOTENSIN II-INDUCED VASCULAR INJURY IN PART VIA INHIBITION OF EGFR AND ERK1/2 ACTIVATION. Journal of Hypertension, 2016, 34, e215.	0.3	0
507	OS 21-01 NOX1 OR NOX4 DELETION PREVENTS TYPE 1 DIABETES-INDUCED ENDOTHELIAL DYSFUNCTION. Journal of Hypertension, 2016, 34, e235.	0.3	0
508	OS 21-06 THREE-MONTH EXPOSURE TO ENDOTHELIN-1 OVEREXPRESSION INCREASES BLOOD PRESSURE AND CAUSES SMALL ARTERY INJURY. Journal of Hypertension, 2016, 34, e236.	0.3	0
509	PS 07-16 CROSSTALK BETWEEN ALDOSTERONE-STIMULATED MINERALOCORTICOID RECEPTOR AND ANGIOTENSIN RECEPTOR PATHWAYS PLAYS A ROLE IN ALDOSTERONE-INDUCED VASCULAR INJURY. Journal of Hypertension, 2016, 34, e287-e288.	0.3	0
510	SY 15-1 MECHANISM OF ENDOTHELIN-1 REGULATION IN HYPERTENSION. Journal of Hypertension, 2016, 34, e371.	0.3	0
511	MPS 18-02 ENDOTHELIN-1 OVEREXPRESSION PRESERVES ENDOTHELIAL FUNCTION IN MICE WITH VASCULAR SMOOTH MUSCLE CELL-SPECIFIC DELETION OF PPAR-GAMMA. Journal of Hypertension, 2016, 34, e423.	0.3	0
512	MPS 18-08 MAPPING OF CHROMOSOME 2 REGIONS LINKED TO VASCULAR INFLAMMATION USING CONGENIC RATS. Journal of Hypertension, 2016, 34, e425.	0.3	0
513	Update From the Editors to Our Readers. American Journal of Hypertension, 2017, 30, 1-2.	1.0	0
514	Response by Caillon et al to Letter Regarding Article, â€œÎ³Î´ T Cells Mediate Angiotensin II-Induced Hypertension and Vascular Injuryâ€. Circulation, 2017, 136, 2200-2201.	1.6	0
515	Reply. Journal of Hypertension, 2017, 35, 2327-2328.	0.3	0
516	Jacques Genest Sr. Hypertension, 2018, 71, 548-549.	1.3	0
517	A3964 Identification of chromosome 2 differentially expressed aortic genes linked to vascular inflammation using congenic rats fed a normal and high-salt diet. Journal of Hypertension, 2018, 36, e25.	0.3	0
518	A3952 Circulating miR-26a-5p and let-7g-5p are potential biomarkers of chronic kidney disease. Journal of Hypertension, 2018, 36, e138-e139.	0.3	0
519	A3978 miR-338â€“3p down-regulation was identified in small arteries of hypertensive patients with chronic kidney disease. Journal of Hypertension, 2018, 36, e139.	0.3	0
520	A7958 Prevalence and clinical characteristics of patients with treatment resistant hypertension by region. Journal of Hypertension, 2018, 36, e306.	0.3	0
521	In Memoriam Jacques Genest Sr, C.C., MD, MACP, FRCPC 1919â€“2018. American Journal of Hypertension, 2018, 31, 385-386.	1.0	0
522	From the Editor-in-Chief: Issue at a glance. American Journal of Hypertension, 2021, 34, 1-2.	1.0	0

#	Article	IF	Citations
523	OUP accepted manuscript. American Journal of Hypertension, 2021, 34, 1245-1246.	1.0	0
524	From the Editor-in-Chief: Issue at a Glance. American Journal of Hypertension, 2021, 34, 123-124.	1.0	0
525	From the Editor-in-Chief: Issue at a Glance. American Journal of Hypertension, 2021, 34, 229-230.	1.0	0
526	From the Editor-in-Chief: Issue at a Glance. American Journal of Hypertension, 2021, 34, 429-431.	1.0	0
527	From the Editor-in-Chief: Issue at a Glance. American Journal of Hypertension, 2021, 34, 565-566.	1.0	0
528	From the Editor-in-Chief: Issue at a Glance. American Journal of Hypertension, 2021, 34, 667-668.	1.0	0
529	From the Editor-in-Chief: Issue at a Glance. American Journal of Hypertension, 2021, 34, 891-892.	1.0	0
530	Peroxisome proliferator activated receptors, inflammation, the vasculature and the heart. , 2003, , 337-348.		0
531	Endothelin Antagonists. , 2005, , 733-735.		0
532	Remodeling of Resistance Arteries in Hypertension. , 2005, , 132-136.		0
533	Angiotensin II and Inflammation. , 2007, , 91-110.		0
534	Role of Endothelin-1 in Hypertension. , 2007, , 245-257.		0
535	Intracellular Signaling Pathways and Peroxisome Proliferator-Activated Receptors in Vascular Health in Hypertension and in Diabetes. Oxidative Stress and Disease, 2007, , 195-210.	0.3	0
536	Interleukin-2 Enhances Angiogenesis and Preserves Cardiac Function Following Myocardial infarction. Blood, 2010, 116, 2786-2786.	0.6	0
537	Abstract 60: Reduced Macrophage-dependent Inflammation Improves Endothelial Function and Vascular Remodeling, Oxidative Stress and Inflammation in a Model Of Endothelin-1 Induced Vascular Injury. Hypertension, 2012, 60, .	1.3	0
538	Effect of Antihypertensive Treatment on Structure and Function of Resistance Arteries in Essential Hypertensive Patients. , 1994, , 323-332.		0
539	Abstract 083: Î³/Î´ T Cells Play a Role in Development of Hypertension. Hypertension, 2016, 68, .	1.3	0
540	Abstract P218: Induction of Human Endothelin-1 Overexpression for 3 Months Causes Blood Pressure Rise and Small Artery Endothelial Dysfunction and Stiffening. Hypertension, 2016, 68, .	1.3	0

#	Article	IF	Citations
541	Abstract P220: Matrix Metalloproteinase 2 Knockout Protects from Angiotensin II-induced Vascular Injury. Hypertension, 2016, 68, .	1.3	0
542	Abstract P225: Nox1 or Nox4 Deletion Prevents Type-1 Diabetes-induced Endothelial Dysfunction. Hypertension, 2016, 68, .	1.3	0
543	Abstract P227: Mapping of Chromosome 2 Regions Linked to Vascular Inflammation Using Congenic Rats. Hypertension, 2016, 68, .	1.3	0
544	Endotheliumâ€dependent vasorelaxation and blood pressure are preserved in mice with chronic hyperendothelinemia. FASEB Journal, 2018, 32, lb327.	0.2	0
545	Regular exercise reduces adipose tissue inflammation and improves glycemic control in Western dietâ€fed mice despite hyperendothelinemia. FASEB Journal, 2018, 32, lb570.	0.2	0
546	Abstract P283: Gamma Delta T Cells Drive CD4 + and CD8 + T Cell Activation in Hypertension. Hypertension, 2018, 72, .	1.3	0
547	Immune Mechanisms in Vascular Remodeling in Hypertension. Updates in Hypertension and Cardiovascular Protection, 2020, , 85-94.	0.1	0
548	OUP accepted manuscript. American Journal of Hypertension, 2022, 35, 1-2.	1.0	0
549	OUP accepted manuscript. American Journal of Hypertension, 2022, 35, 113-114.	1.0	0
550	From the Editor-in-Chief: Issue at a Glance. American Journal of Hypertension, 2022, 35, 209-210.	1.0	0
551	Abstract 167: Mapping of Chromosome 2 Regions Linked to Vascular Inflammation Using Congenic Rats. Hypertension, 2012, 60, .	1.3	0
552	Abstract 16: Adoptive Transfer of T Lymphocytes Prevents Angiotensin II-induced Vascular Stiffness in rag-1 Knockout Mice.. Hypertension, 2012, 60, .	1.3	0
553	Abstract 264: Erythropoietin-induced Hypertension and Vascular Injury in Mice Overexpressing Human Endothelin-1 Was Attenuated by Exercise. Hypertension, 2012, 60, .	1.3	0
554	Abstract 43: A Functional Angiotensin Type 1a Receptor Is Required for Aldosterone to Induce Small Artery Endothelial Dysfunction, Inflammation and Oxidative Stress. Hypertension, 2012, 60, .	1.3	0
555	Abstract 449: Develoment of Endothelin-1 Induced Aneurysms in High-Fat Diet-Fed Apolipoprotein E Knockout Mice Through a Mechanism Involving Oxidative Stress and Inflammatory Cell Infiltration. Hypertension, 2012, 60, .	1.3	0
556	Abstract 345: Role Of Vascular Smooth Muscle Cell PPARÎ³ In Aldosterone-induced Vascular Injury. Hypertension, 2014, 64, .	1.3	0